GoDaddy Founder, Bob Parsons Details Journey of Healing Through Psychedelics in Exclusive Interview With PSYC
June 15 2022 - 8:30AM
InvestorsHub NewsWire
GoDaddy Founder, Bob Parsons Details Journey of
Healing Through Psychedelics in Exclusive Interview With
PSYC
LAS VEGAS, NV -- June 15, 2022 -- InvestorsHub
NewsWire -- PSYC Corporation
(OTCPink:
PSYC) (“PSYC” or the “Company”) a media leader for the emerging
sector of medicinal psychedelics and authorities behind Psychedelic
Spotlight, a top ranking psychedelic news and
information platform, is pleased to announce that the 5th episode
of their talk show series, Spotlight In Focus, will be headlined by an exclusive
interview with American entrepreneur, billionaire, and founder of
GoDaddy, Bob Parsons.
The interview, conducted by PSYC CEO, David Flores,
highlights the journey of Parsons finding his way “back home” with
the help of psychedelic-assisted therapy, his personal battle with
PTSD, which, as Parsons explains during the interview, can be
traced back to the traumatic events he witnessed and experienced
during his service in Vietnam as a proud and decorated member of
the United States Marine Corps.
Parsons and Flores also discuss the important role
therapy and counseling play alongside psychedelics when treating
specific mental health conditions like PTSD and how, in Parsons’
case, the combination of the two were critical in helping him
overcome the challenges he faced with his
PTSD.
In addition to the segment dedicated to Parsons, the
episode also features an exclusive inside look at Radiance Wellness
in St. Louis, where Dr. Zinia Thomas is leveraging the use of
ketamine therapy to treat patients suffering from treatment
resistant depression, anxiety, addiction, and chronic
pain.
Psychedelic Spotlight Video Director, Matthew
Dunehoo, also speaks with Numinus Wellness CEO and Founder, Payton
Nyquvest and music artist, Justin Boreta, to learn more about Music
as Medicine, a series of ceremonial concerts exploring the role
music plays in psychedelic-assisted therapy and mental health, and
on the heels of the first event held in Los Angeles last
month.
“With Spotlight in Focus, we seek to share these
amazing stories in a disarming and empathetic context. People need
to feel at ease to be open to changing their minds. We present our
guests and their expertise and experiences as approachably as
possible. The concept is ever-evolving, but I believe there’s power
in stripping away historically distracting tropes from the
narrative, focusing instead on universally relatable truths.
Psychedelic medicine and the conversation around the mental health
crisis are still highly stigmatized. Significant shifts in
perception demand acknowledgement and support from the widest
audience possible. We are grateful for the chance to engage and
present an array of voices, from mainstream psychedelic advocates
like Mr. Parsons, to addicts like friend of the show Brittany who
are up against dehumanizing odds in seeking lasting dignity and
wellness,” said Dunehoo.
PSYC CEO David Flores elaborated further: “The
wonderfully unique stories that we’ve been fortunate enough to
feature and tell in this latest episode of Spotlight in Focus
strongly reinforces the general excitement and optimism we maintain
regarding the psychedelic sector and its potential to transform the
lives of so many people. We are especially grateful to have the
opportunity for Psychedelic Spotlight to help share Bob Parsons'
inspirational story of healing through psychedelic-assisted
therapy. His success as an entrepreneur and philanthropist afforded
him a respected voice that reaches millions of people worldwide.
For him to come out recently and advocate for psychedelic-assisted
healing based on his own personal success is something that, we
believe, can help create more momentum behind increasing
accessibility to resources focused on psychedelic-assisted healing
throughout society.”
Flores concluded with: “There remains a tremendous
amount of work and advocacy left to be done in order to guide
psychedelic-assisted therapy into the mainstream. And I truly
believe the platform we’ve established through Psychedelic
Spotlight, and the very real stories we’re able to tell through
production pieces like Spotlight in Focus, will be integral in
helping pave the way for the progress we fully intend to contribute
to in the years to come.”
The 5th episode of Spotlight in Focus can
be viewed by following this link: SIF
E.5
About PSYC
Corporation (OTCPink:
PSYC)
At PSYC
Corporation we are integrating media, creativity, and technology to
develop and deploy thought-provoking ideas and solutions that are
fostering and transforming the approach to some of society’s most
pressing matters.
PSYC has
expressed its intent and commitment to positioning itself at the
forefront of the psychedelic revolution and as a resource center
for discovering and understanding the latest research and business
opportunities surrounding psychedelic inspired medicines. In
conjunction with the FDA’s more open-minded approach to psychedelic
medicines, and as several major U.S. cities continue to approve the
decriminalization of psilocybin, we believe investors are
speculating that the psychedelic boom could be bigger than that of
cannabis. PSYC is your source for current investment related news
specific to psychedelic medicines and cutting-edge research
improving overall health, moving this sector into the
mainstream.
We are
dedicated to a forward-thinking approach that embraces
groundbreaking new technology and innovations and through the
vision of business development we intend to continue to evolve into
these unchartered territories as the industry leaders of the
future.
Forward-Looking Statements Disclaimer:
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. In some
cases, you can identify forward-looking statements by the following
words: "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "ongoing," "plan," "potential,"
"predict," "project," "should," "will," "would," or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. Forward-looking
statements are not a guarantee of future performance or results and
will not necessarily be accurate indications of the times at, or
by, which such performance or results will be achieved.
Forward-looking statements are based on information available at
the time the statements are made and involve known and unknown
risks, uncertainty and other factors, including the effect of
COVID-19 and the success of the current vaccine distribution, the
adverse effect of the Omicron variant, that may cause our results,
levels of activity, performance or achievements to be materially
different from the information expressed or implied by the
forward-looking statements in this press release. This press
release should be considered in light of all filings of the Company
that are disclosed on the OTC Markets.com website and is not
incorporated by reference into such
reports.
Disclaimer: PSYC Corporation does not in any way encourage or
condone the use, purchase, sale or transfer of any illegal
substances, nor do we encourage or condone partaking in any
unlawful activities. We support a harm reduction approach for the
purpose of education and promoting individual and public safety. If
you are choosing to use psychedelic substances, please do so
responsibly.
Corporate
Contact:
PSYC
Corporation (PSYC)
www.psyccorporation.com
(702)
761-6716
info@psyccorporation.com
OTCPINK: PSYC
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Aug 2024 to Sep 2024
PSYC (PK) (USOTC:PSYC)
Historical Stock Chart
From Sep 2023 to Sep 2024